Page 4 - Stephens Yoder News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pieris Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update ACCESSWIRE 17 May 2021, 21:05 GMT+10 COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON MONDAY, MAY 17, 2021 AT 8:00 AM EDT PRS-060/AZD1402 dosed to first patient in phase 2a study Cinrebafusp alfa (PRS-343) phase 2 study expected to begin this summer Announced license and collaboration agreement with Boston Pharmaceuticals for PRS-342, a preclinical 4-1BB/GPC3 immuno-oncology bispecific; Pieris to receive $10 million upfront payment and is eligible to receive up to approximately $353 million in mil...

Penny Stocks To Buy According To Analysts Whether you love penny stocks or hate them, you can’t argue with the fact that big money can be made. By definition, the term itself references stocks to buy for less than $5. So even the slightest 50 cent move from the highest-priced penny stock is a near-market-beating gain. For the most part, newer retail traders actively learn how to day trade and start by focusing on cheap stocks to watch. Since it doesn’t take a whole lot of capital to buy penny stocks, they’ve become somewhat of a “go-to” for mom-and-pop investors. Thi...

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting Durable anti-tumor activity in heavily pre-treated patient population ?including "cold" and HER2-low expressing tumors Dose-dependent immune activation and 4-1BB modulation in both HER2-high and HER2-low expressing patients PRS-344/S095012 preclinical BOSTON, MA / ACCESSWIRE / April 10, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnolo...